- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
King v. Burwell Decision Could Exacerbate Disparities in the US
Although the decision in King v. Burwell will not directly affect states that have set up their own health insurance exchanges, they could see some benefits, according to David Blumenthal, MD, chief executive officer of The Commonwealth Fund.
Although the decision in King v. Burwell will not directly affect states that have set up their own health insurance exchanges, they could see some benefits, according to David Blumenthal, MD, chief executive officer of The Commonwealth Fund.
He explained that a win for the plaintiffs could create “a very odd reversal” of the typical way subsidies are used in the United States. Wealthy states like New York and California, which have set up their own exchanges, would continue to receive subsidies, while less well-to-do states like Alabama and Mississippi, on the federally facilitated marketplace, will no longer get subsidies.
“However, they continue to pay taxes,” Dr Blumenthal said. “This strikes me as a bad fiscal policy for the United States.”
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More
